The aim of this work was to investigate how the incorporation of a hydrophilic cyclodextrin (CD) inside erodible hydrophilic matrices affects drug-release behavior and transport properties through artificial and biological membranes. To this purpose, Diclofenac (Dic) was incorporated in poly(ethyleneoxide) (PEO) matrices as poorly soluble free acid (DicH) or freely water-soluble sodium salt (DicNa) in the presence or absence of hydroxypropyl-beta-cyclodextrin (HPbetaCD). Preliminary experiments demonstrated that HPbetaCD increased Dic apparent solubility as a function of its amount in the solution and medium pH due to complex formation. Permeation of ionized Dic through porcine buccal mucosa gave higher values of J(SS) and K(p) as compared to silicon membranes and depended on the presence of HPbetaCD. Incorporation of HPbetaCD in PEO tablets resulted in an increase of release rate for both forms of Dic whereas cumulative drug flux through silicon membranes and porcine buccal mucosa was increased for DicH and decreased for DicNa. An interpretation of this behavior was attempted on the basis of the presence of a transport resistance occurring inside the hydrated gel matrix as modified by the presence of CD. In conclusion, this study has demonstrated that the use of CDs in hydrophilic matrices intended for oral drug delivery should be rationalized since their modulator effect relies not only on drug-dissolution rate but also on environment where drug release occurs (aqueous medium, membrane interface).

Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: Role of cyclodextrins and implications in oral drug delivery / Miro, Agnese; A., Rondinone; A., Nappi; Ungaro, Francesca; Quaglia, Fabiana; LA ROTONDA, MARIA IMMACOLATA. - In: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. - ISSN 0939-6411. - STAMPA. - 72:1(2009), pp. 76-82. [10.1016/j.ejpb.2008.12.006]

Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: Role of cyclodextrins and implications in oral drug delivery.

MIRO, AGNESE;UNGARO, FRANCESCA;QUAGLIA, FABIANA;LA ROTONDA, MARIA IMMACOLATA
2009

Abstract

The aim of this work was to investigate how the incorporation of a hydrophilic cyclodextrin (CD) inside erodible hydrophilic matrices affects drug-release behavior and transport properties through artificial and biological membranes. To this purpose, Diclofenac (Dic) was incorporated in poly(ethyleneoxide) (PEO) matrices as poorly soluble free acid (DicH) or freely water-soluble sodium salt (DicNa) in the presence or absence of hydroxypropyl-beta-cyclodextrin (HPbetaCD). Preliminary experiments demonstrated that HPbetaCD increased Dic apparent solubility as a function of its amount in the solution and medium pH due to complex formation. Permeation of ionized Dic through porcine buccal mucosa gave higher values of J(SS) and K(p) as compared to silicon membranes and depended on the presence of HPbetaCD. Incorporation of HPbetaCD in PEO tablets resulted in an increase of release rate for both forms of Dic whereas cumulative drug flux through silicon membranes and porcine buccal mucosa was increased for DicH and decreased for DicNa. An interpretation of this behavior was attempted on the basis of the presence of a transport resistance occurring inside the hydrated gel matrix as modified by the presence of CD. In conclusion, this study has demonstrated that the use of CDs in hydrophilic matrices intended for oral drug delivery should be rationalized since their modulator effect relies not only on drug-dissolution rate but also on environment where drug release occurs (aqueous medium, membrane interface).
2009
Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: Role of cyclodextrins and implications in oral drug delivery / Miro, Agnese; A., Rondinone; A., Nappi; Ungaro, Francesca; Quaglia, Fabiana; LA ROTONDA, MARIA IMMACOLATA. - In: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. - ISSN 0939-6411. - STAMPA. - 72:1(2009), pp. 76-82. [10.1016/j.ejpb.2008.12.006]
File in questo prodotto:
File Dimensione Formato  
2009 EJPB diclofenac in PEO CD.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 575.19 kB
Formato Adobe PDF
575.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/339119
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 25
social impact